CCO Independent Conference Coverage

Slides:



Advertisements
Similar presentations
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
Advertisements

MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.
Alliance A021101: Preoperative mFOLFIRINOX + Chemoradiation in Borderline Resectable Pancreatic Cancer CCO Independent Conference Highlights of the 2015.
POPLAR: Atezolizumab Improved Survival vs Docetaxel in Patients With Advanced NSCLC and Increasing Levels of PD-L1 Expression CCO Independent Conference.
CCO Independent Conference Coverage*: The 2015 Annual Meeting of the CTRC-AACR San Antonio Breast Cancer Symposium, December 8-12, 2015 San Antonio, Texas.
KEYNOTE-021: Pembrolizumab + Ipilimumab Active in Previously Treated Advanced NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC.
CCO Independent Conference Coverage
CCO Independent Conference Coverage
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Fractionated Dosing Optimizes CAR T-Cell Therapy in Adult Relapsed/Refractory.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Rovalpituzumab Tesirine Safe, Active in Previously Treated SCLC *CCO.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase III MF07-01 Trial: Impact of Initial Local Resection on Stage.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 KRISTINE: Neoadjuvant T-DM1 + Pertuzumab vs Chemotherapy With Trastuzumab.
Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC
CCO Independent Conference Highlights
CCO Independent Conference Highlights
MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy CCO Independent Conference.
CCO Independent Conference Coverage
Phase II SAKK 35/10 Trial: Rituximab Plus Lenalidomide Shows Durable Activity in Untreated Follicular Lymphoma New Findings in Hematology: Independent.
CCO Independent Conference Highlights
CCO Independent Conference Highlights
: Mogamulizumab in R/R Adult T-Cell Leukemia-Lymphoma
KEYNOTE-028: Pembrolizumab in PD-L1+, ER+/HER2- Breast Cancer
Phase II HALO-202: nab-Paclitaxel and Gemcitabine ± PEGPH20 in Untreated Metastatic Pancreatic Ductal Adenocarcinoma CCO Independent Conference Highlights*
CCO Independent Conference Coverage
CCO Independent Conference Highlights
PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent.
CCO Independent Conference Coverage
Neoadjuvant Palbociclib + Anastrozole in ER+/HER2- Breast Cancer
CCO Independent Conference Highlights
CCO Independent Conference Highlights
19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL
Phase III SOLE: Continuous vs Intermittent Extended Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer CCO Independent Conference Highlights*
NCI 9177: Risk-Adapted DA-EPOCH-R in Adults With Burkitt Lymphoma
KEYNOTE-086 (Cohort A): Phase II Evaluation of Pembrolizumab Monotherapy in Heavily Pretreated Metastatic TNBC CCO Independent Conference Highlights* of.
CCO Independent Conference Coverage
Lenalidomide Shows Promising Activity in Recurrent CNS Lymphoma
CCO Independent Conference Coverage
ELOQUENT-2: Elotuzumab + Len/Dex in R/R MM
CCO Independent Conference Coverage
IMvigor 210 (Cohort 1): First-line Atezolizumab in Cisplatin-Ineligible Metastatic Urothelial Carcinoma CCO Independent Conference Coverage* of the 2016.
Immunoscore Prognostic in Colon Cancer
CCO Independent Conference Coverage
ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
CCO Independent Conference Highlights
CCO Independent Conference Coverage
STAMPEDE: Docetaxel Significantly Improves Survival in Men With Hormone-Naive Prostate Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.
Phase I/II Study of Lorlatinib in Advanced ALK+ or ROS1+ NSCLC
Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
CREATE-X: Adjuvant Capecitabine in HER2-Negative Breast Cancer
CCO Independent Conference Coverage
CCO Independent Conference Coverage
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*
NCI/CTEP 7435: Eribulin Active, Tolerable in Urothelial Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,
New Findings in Hematology: Independent Conference Coverage
Local Consolidative Therapy in Oligometastatic NSCLC With No Progression on First-line Systemic Treatment CCO Independent Conference Coverage* of the 2016.
SIRveNIB: Randomized Phase III Trial of Selective Internal Radiation Therapy vs Sorafenib in Locally Advanced HCC CCO Independent Conference Highlights*
KEYNOTE-087: Pembrolizumab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma New Findings in Hematology: Independent Conference Coverage.
CCO Independent Conference Highlights
ESPAC-4: Adjuvant Gemcitabine/ Capecitabine Improves 5-Yr Survival vs Gemcitabine Alone in Resected Pancreatic Ductal Carcinoma CCO Independent Conference.
CCO Independent Conference Coverage
Combined Inhibition of PD-L1, MEK, and BRAF Active in Advanced Melanoma CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -
KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
KEYNOTE-023: Pembrolizumab + Lenalidomide + Dexamethasone Shows Promising Activity and Safety in R/R MM CCO Independent Conference Coverage* of the 2016.
CCO Independent Conference Coverage
CheckMate 204: Nivolumab + Ipilimumab in Pts With Advanced Melanoma and Asymptomatic, Untreated Brain Metastases CCO Independent Conference Highlights*
CCO Independent Conference Coverage
Trifluridine/Tipiracil (TAS-102) Improves Survival in Patients With Metastatic CRC and Mild Renal/Hepatic Impairment: Subgroup Analysis of RECOURSE CCO.
New Findings in Hematology: Independent Conference Coverage
Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination With Chemotherapy in Early-Stage TNBC CCO Independent Conference Highlights*
Presentation transcript:

Retreatment With Radium-223 Safe, Showing Activity in Patients With CRPC and Bone Metastases CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 *CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs. CRPC, castration-resistant prostate cancer. This activity is supported by educational grants from Amgen, Ariad, Bayer Healthcare Pharmaceuticals, Celgene Corporation, Genentech, Incyte, Merck, and Taiho Pharmaceuticals.

Radium-223 Retreatment in CRPC: Study Background Radium-223: alpha-emitting radiopharmaceutical that exerts potent cytotoxic effects on bone metastases In phase III ALSYMPCA trial, improved OS by 3.6 mos (P < .001), delayed time to first symptomatic skeletal event by 5.8 mos (P < .001), and had favorable safety profile for CRPC pts with bone metastases[1,2] Outcomes based on one 50-kBq/kg injection Q4W for 6 injections[1,2] Data suggest radium-223 retreatment may provide added benefit to pts who received initial 6-injection course[3] Current international, prospective, open-label phase I/II study evaluated efficacy and safety of radium-223 retreatment in pts with CRPC and bone metastases[4] CRPC, castration-resistant prostate cancer. 1. Parker C, et al. N Engl J Med. 2013;369:213-223. 2. Sartor O, et al. Lancet Oncol. 2014;15:738-746. 3. Sartor O, et al. ASCO GU 2016. Abstract 197. 4. Sartor O, et al. ASCO 2016. Abstract 5074. Slide credit: clinicaloptions.com

Radium-223 Retreatment in CRPC: Study Design Pts (N = 44) with metastatic CRPC who experienced radiographic or clinical progression following initial radium-223 treatment enrolled January 2014 to June 2015 Second 6-injection course of radium-223 50-kBq/kg Q4W administered > 30 days after end of initial course Pts actively followed up to 2 yrs after last radium-223 injection, with long- term follow up carried out to 7 yrs Primary endpoint: safety Exploratory endpoints: time to radiographic bone progression, radiographic PFS, OS, time to first SSE, SSE-free survival, time to pain progression Findings from this study compared with those from phase III ALSYMPCA trial CRPC, castration-resistant prostate cancer; SSE, symptomatic skeletal event. Slide credit: clinicaloptions.com Sartor O, et al. ASCO 2016. Abstract 5074.

Radium-223 Retreatment in CRPC: Eligibility Criteria CRPC and bone metastases Completion of 6 initial radium-223 injections with: No bone progression during initial treatment Radiographic or clinical progression after initial treatment Adequate hematologic function Pts ineligible if grade 3/4 AEs during or after initial radium-223 treatment that did not resolve or led to discontinuation Concomitant chemotherapy or initiation of abiraterone or enzalutamide treatment not permitted Other agents allowed based on investigator discretion AE, adverse event; CRPC, castration-resistant prostate cancer. Slide credit: clinicaloptions.com Sartor O, et al. ASCO 2016. Abstract 5074.

Radium-223 Retreatment in CRPC: Baseline Characteristics Retreatment Study (N = 44) ALSYMPCA (N = 614) Median age, yrs (range) 71 (52-91) 71 (49-90) ECOG PS 0/1/≥ 2, % 32/61/7 27/60/13 < 6/6-20/> 20 bone metastases, % 41/34/25 16/43/41 Prior treatment, % Docetaxel Abiraterone Enzalutamide Bisphosphonates Denosumab 45 61 30 11 48 57 NA 20 Concurrent treatment, % 27 9 16 Median PSA, μg/L 68 146 CRPC, castration-resistant prostate cancer; ECOG, Eastern Cooperative Oncology Group; NA, not applicable; PS, performance status; PSA, prostate-specific antigen. Slide credit: clinicaloptions.com Sartor O, et al. ASCO 2016. Abstract 5074.

Radium-223 Retreatment in CRPC: Treatment Experience Of the 44 pts who received retreatment: All had received ≥ 2 prior hormonal regimens 45% had received ≥ 1 prior chemotherapy regimen 73% had failed novel hormonal agents (abiraterone, enzalutamide) 66% completed retreatment with all 6 injections Median time from end of initial regimen to retreatment: 6 mos (range: 1.2-17.1 mos) CRPC, castration-resistant prostate cancer. Slide credit: clinicaloptions.com Sartor O, et al. ASCO 2016. Abstract 5074.

Radium-223 Retreatment in CRPC: Safety TEAEs, % Retreatment Study (N = 44) ALSYMPCA (N = 600) All Grades Grade 3 Grade 4 Pts with ≥ 1 TEAE 93 41 7 35 9 Hematologic Anemia Thrombocytopenia Leukopenia Neutropenia 14 2 5 31 12 4 11 3 1 < 1 Nonhematologic (in > 10% of retreatment pts) Fatigue Nausea Diarrhea Decreased appetite Arthralgia Hypertension Back pain Fall Vomiting 27 25 21 18 26 36 6 19 CRPC, castration-resistant prostate cancer; TEAE, treatment-emergent adverse event. Slide credit: clinicaloptions.com Sartor O, et al. ASCO 2016. Abstract 5074.

Radium-223 Retreatment in CRPC: Efficacy Median time to several endpoints not yet reached: radiographic bone progression, OS, time to first SSE, SSE-FS, time to pain progression 5 pts (11%) died through 15.5-mo max OS follow-up 8 pts (14%) experienced first SSE through 14.1-mo max SSE, SSE-free survival follow-up 5 of 36 evaluable pts (14%) had pain progression through 7.3-mo max pain progression follow-up Wk 24 pain progression event rate: 20% CRPC, castration-resistant prostate cancer; SSE, symptomatic skeletal event. Slide credit: clinicaloptions.com Sartor O, et al. ASCO 2016. Abstract 5074.

Radium-223 Retreatment in CRPC: rPFS Median rPFS: 9.9 mos 13 pts had rPFS events, largely consisting of soft tissue tumor progression (n = 8) Only 1 pt with confirmed radiographic bone progression 12.8-mos max follow- up time for rPFS and radiographic bone progression Radiographic PFS 100 80 60 rPFS (%) 40 20 2 4 6 8 10 12 14 CRPC, castration-resistant prostate cancer; rPFS, radiographic PFS. Mos Patients at risk 44 36 29 20 14 3 1 Slide credit: clinicaloptions.com Sartor O, et al. ASCO 2016. Abstract 5074.

Radium-223 Retreatment CRCP: Conclusions Second round of radium-223 treatment following initial course safe and feasible[1] Well tolerated, with minimal hematologic toxicity Low rate of radiographic bone progression Encouraging early effects on OS, time to SSE, pain Investigators conclude positive data warrant analysis of radium-223 retreatment in larger prospective trials[1] Ongoing study to address expanded radium-223 dosing and duration of treatment[2] CRPC, castration-resistant prostate cancer; SSE, symptomatic skeletal event. 1. Sartor O, et al. ASCO 2016. Abstract 5074. 2. ClinicalTrials.gov. NCT02023697. Slide credit: clinicaloptions.com

Go Online for More CCO Coverage of ASCO 2016! Short slideset summaries of all the key data Additional CME-certified analyses with expert faculty commentary on all the key studies in: Breast, genitourinary, and lung cancers Hematologic malignancies Immunotherapy clinicaloptions.com/oncology